Literature DB >> 26370356

Consensus on the management of intracranial germ-cell tumours.

Matthew J Murray1, Ute Bartels2, Ryo Nishikawa3, Jason Fangusaro4, Masao Matsutani3, James C Nicholson5.   

Abstract

The management of intracranial germ-cell tumours is complex because of varied clinical presentations, tumour sites, treatments and outcomes, and the need for multidisciplinary input. Participants of the 2013 Third International CNS Germ Cell Tumour Symposium (Cambridge, UK) agreed to undertake a multidisciplinary Delphi process to identify consensus in the clinical management of intracranial germ-cell tumours. 77 delegates from the symposium were selected as suitable experts in the field and were invited to participate in the Delphi survey, of which 64 (83%) responded to the invitation. Invited participants represented multiple disciplines from Asia, Australasia, Europe, and the Americas. 38 consensus statements encompassing aspects of intracranial germ-cell tumour work-up, staging, treatment, and follow-up were prepared. To achieve consensus, statements required at least 70% agreement from at least 60% of respondents. Overall, 34 (89%) of 38 statements met consensus criteria. This international Delphi approach has defined key areas of consensus that will help guide and streamline clinical management of patients with intracranial germ-cell tumours. Additionally, the Delphi approach identified areas of different understanding and clinical practice internationally in the management of these tumours, areas which should be the focus of future collaborative studies. Such efforts should translate into improved patient outcomes.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26370356     DOI: 10.1016/S1470-2045(15)00244-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  53 in total

1.  Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium.

Authors:  Hirokazu Takami; Kohei Fukuoka; Shintaro Fukushima; Taishi Nakamura; Akitake Mukasa; Nobuhito Saito; Takaaki Yanagisawa; Hideo Nakamura; Kazuhiko Sugiyama; Masayuki Kanamori; Teiji Tominaga; Taketoshi Maehara; Mitsutoshi Nakada; Yonehiro Kanemura; Akio Asai; Hideo Takeshima; Yuichi Hirose; Toshihiko Iuchi; Motoo Nagane; Koji Yoshimoto; Akira Matsumura; Kazuhiko Kurozumi; Hiroyuki Nakase; Keiichi Sakai; Tsutomu Tokuyama; Soichiro Shibui; Yoichi Nakazato; Yoshitaka Narita; Ryo Nishikawa; Masao Matsutani; Koichi Ichimura
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

2.  T2*-based MR imaging (gradient echo or susceptibility-weighted imaging) in midline and off-midline intracranial germ cell tumors: a pilot study.

Authors:  Giovanni Morana; Cesar Augusto Alves; Domenico Tortora; Jonathan L Finlay; Mariasavina Severino; Paolo Nozza; Marcello Ravegnani; Marco Pavanello; Claudia Milanaccio; Mohamad Maghnie; Andrea Rossi; Maria Luisa Garrè
Journal:  Neuroradiology       Date:  2017-11-11       Impact factor: 2.804

3.  Unusual cause of profound weight loss in a young woman.

Authors:  Ashu Rastogi; Pavan Uppula; Kanchan Kumar Mukherjee; Anil Bhansali
Journal:  BMJ Case Rep       Date:  2016-11-22

4.  Treatment and survival of primary intracranial germ cell tumors: a population-based study using SEER database.

Authors:  Steven Denyer; Abhiraj D Bhimani; Shashank N Patil; Andrew Mudreac; Mandana Behbahani; Ankit I Mehta
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-19       Impact factor: 4.553

5.  Primary Central Nervous System Germ Cell Tumors: A Review and Update.

Authors:  Kaleigh Fetcko; Mahua Dey
Journal:  Med Res Arch       Date:  2018-03-15

Review 6.  Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors.

Authors:  Mohammad H Abu Arja; Joseph R Stanek; Jonathan L Finlay; Mohamed S AbdelBaki
Journal:  Childs Nerv Syst       Date:  2018-08-03       Impact factor: 1.475

7.  Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.

Authors:  Jason Fangusaro; Shengjie Wu; Shannon MacDonald; Erin Murphy; Dennis Shaw; Ute Bartels; Soumen Khatua; Mark Souweidane; Hsiao-Ming Lu; David Morris; Ashok Panigrahy; Arzu Onar-Thomas; Maryam Fouladi; Amar Gajjar; Girish Dhall
Journal:  J Clin Oncol       Date:  2019-09-23       Impact factor: 44.544

8.  Clinical features, radiologic findings, and treatment of pediatric germ cell tumors involving the basal ganglia and thalamus: a retrospective series of 15 cases at a single center.

Authors:  Mengmeng Wang; Peizhi Zhou; Shizhen Zhang; Xueyou Liu; Liang Lv; Zeming Wang; Feng Ye; Yan Ju; Shu Jiang
Journal:  Childs Nerv Syst       Date:  2017-10-24       Impact factor: 1.475

Review 9.  Current Advances and Future Perspectives of Cerebrospinal Fluid Biopsy in Midline Brain Malignancies.

Authors:  Yimin Pan; Wenyong Long; Qing Liu
Journal:  Curr Treat Options Oncol       Date:  2019-11-29

10.  So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?

Authors:  Masayuki Kanamori; Hirokazu Takami; Shigeru Yamaguchi; Takashi Sasayama; Koji Yoshimoto; Teiji Tominaga; Akihiro Inoue; Naokado Ikeda; Atsushi Kambe; Toshihiro Kumabe; Masahide Matsuda; Shota Tanaka; Manabu Natsumeda; Ken-Ichiro Matsuda; Masahiro Nonaka; Jun Kurihara; Masayoshi Yamaoka; Naoki Kagawa; Naoki Shinojima; Tetsuya Negoto; Yukiko Nakahara; Yoshiki Arakawa; Seiji Hatazaki; Hiroaki Shimizu; Atsuo Yoshino; Hiroshi Abe; Jiro Akimoto; Yu Kawanishi; Tomonari Suzuki; Atsushi Natsume; Motoo Nagane; Yukinori Akiyama; Dai Keino; Tadateru Fukami; Takahiro Tomita; Kohei Kanaya; Tsutomu Tokuyama; Shuichi Izumoto; Mitsutoshi Nakada; Daisuke Kuga; Shohei Yamamoto; Ryogo Anei; Takeo Uzuka; Junya Fukai; Noriyuki Kijima; Keita Terashima; Koichi Ichimura; Ryo Nishikawa
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.